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Abstract
Background: Microarray technology is a high-throughput method for measuring the expression levels of thousand of 
genes simultaneously. The observed intensities combine a non-specific binding, which is a major disadvantage with 
microarray data. The Affymetrix GeneChip assigned a mismatch (MM) probe with the intention of measuring non-
specific binding, but various opinions exist regarding usefulness of MM measures. It should be noted that not all 
observed intensities are associated with expressed genes and many of those are associated with unexpressed genes, of 
which measured values express mere noise due to non-specific binding, cross-hybridization, or stray signals. The 
implicit assumption that all genes are expressed leads to poor performance of microarray data analyses. We assume 
two functional states of a gene - expressed or unexpressed - and propose a robust method to estimate gene 
expression states using an order relationship between PM and MM measures.
Results: An indicator 'probability of a gene being expressed' was obtained using the number of probe pairs within a 
probe set where the PM measure exceeds the MM measure. We examined the validity of the proposed indicator using 
Human Genome U95 data sets provided by Affymetrix. The usefulness of 'probability of a gene being expressed' is 
illustrated through an exploration of candidate genes involved in neuroblastoma prognosis. We identified the 
candidate genes for which expression states differed (un-expressed or expressed) when compared between two 
outcomes. The validity of this result was subsequently confirmed by quantitative RT-PCR.
Conclusion: The proposed qualitative evaluation, 'probability of a gene being expressed', is a useful indicator for 
improving microarray data analysis. It is useful to reduce the number of false discoveries. Expression states - expressed 
or unexpressed - correspond to the most fundamental gene function 'On' and 'Off', which can lead to biologically 
meaningful results.
Background
Microarray technology is a high-throughput method for
measuring the expression levels of thousand of genes
simultaneously. Recent completion of the MicroArray
Quality Control (MAQC) project ensures intra-platform
consistency across test sites as well as a high level of inter-
platform concordance [1]. As a result, microarrays are
increasingly being used in the medical and biological
fields as a powerful tool for disease diagnosis, identifying
biomarkers, and studying gene function. However,
observed intensities combine non-specific bindings
including cross-hybridization or stray signals, which is a
major disadvantage of microarray data.
The Affymetrix GeneChip microarray, in which Oligo-
nucleotides of 25 bp are used to probe genes, is designed
to include measures that allow the evaluation of non-spe-
cific hybridization. Each gene will be represented by
11~20 pairs of olligonucleotides referred to as a probe set
(for example, the Human Genome U95 array uses 16
probe pairs and the Human Genome U133 Plus 2.0 array
uses 11 probe pairs). Each of the probe pairs in a probe
set consists of a perfect match (PM) and a mismatch
(MM) probe. The PM probes are designed to bind per-
fectly to the gene of interest and the MM probes are cre-
ated by changing the middle (13th) base to disrupt the
bulk of specific hybridization [2]. However, opinions vary
regarding the usefulness of MM measures.
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Page 2 of 14Background correction algorithms for the Affymetrix
GeneChip microarray may be classified into two groups:
those that use MM measures (e.g., dChip difference mode
[3] as well as MAS5 [4] and its later, improved version
PLIER [5]) and those that do not (dChip PM mode [6],
RMA (Robust Multi-array Analysis) [7] and its modified
version, PM-only GC-RMA [8]). RMA and MAS5 are
representative algorithms used for background correc-
tion. With the RMA method, only PM is used to obtain a
corrected intensity. MAS5 was originally provided as a
default measure by Affymetrix, in which PMs are cor-
rected by subtracting MMs, but many researchers
pointed out that direct subtraction of MM from PM is
unlikely to be useful [9]. The preprocessing step affects
the stochastic properties of the final statistical summaries
[10]. Biologists who want to analyze microarray data
might be bewildered with the availability of so many pre-
processing procedures with varying results [11].
Biologically, it is likely that not all observed intensities
are associated with expressed genes -- that is, many of
those are associated with unexpressed genes, of which
measured values simply express noise due to non-specific
binding, cross-hybridization, or stray signal [12]. It has
been reported that only 30-40% of the genes [13] --
around 10,000-15,000 genes in total [14]-- are expressed
in human cell lines in vitro. Identifying probe sets associ-
ated with un-expressed genes would allow the subse-
quent statistical analysis to be carried out with greater
efficiency. For example, in an analysis aimed at finding
differentially expressed genes, filtering out these probe
sets prior to analysis contributed to a decreased number
of false discoveries [12,15].
In previous work, we proposed a mathematical model
based on the assumption that a gene has two separate
functional states - 'On' means a gene is really expressed
and 'Off ' means a gene is un-expressed - for identifying
differentially expressed genes between two cell types [16].
Furthermore, we proposed to identify 'Off ' genes using an
order relationship between PM and MM measures using
Affymetrix GeneChip probe level data [17]. We applied
the 'On/Off ' model to real medical or biological data and
obtained meaningful results [18-20]. In this study, we
propose to quantify a gene as being expressed using a
Weibull-Normal mixture distribution with two compo-
nents corresponding to the separate states 'On' and 'Off '.
The probability of a gene being 'On' is obtained from the
posterior probability using this Weibull-Normal mixture
distribution. We examine the advantage of our method
over the detection call of MAS5 using the data sets of
Human Genome U95 provided by Affymetrix. We imple-
ment our proposed methods of microarray analysis to
explore candidate genes involved in neuroblastoma prog-
nosis.
The symbol X denotes the number of pairs in a probe
set satisfying PM >MM :X = #{j|PMj >MMj, j = 1, , J},
where J is the number of probe pairs in a probe set.
Results
Estimation of Weibull-Normal density function
Figure 1 illustrates the relationship between gene expres-
sion level and the value of X, where the RMA summa-
rized value was used as the measure of gene expression
level (signal intensity). It shows that a gene with high
expression level has larger X -- that is, the gene is in the
'On' state. Similarly, a gene with small X ('Off ' gene) has
low expression intensity. However, not all genes with
large X ('On' genes) evidence high expression levels. Fig-
ures 2A-C show PM and MM measurements for probe
sets in which summarized expression levels are high,
moderate, or low, respectively. Each probe set was sam-
pled randomly from the high, moderate, or low expres-
sion group. If gene expression level is high enough, the
PM value is adequately larger than the MM value in every
probe pair, and it is possible in principle to separate a sig-
nal of specific binding from one of non-specific binding
(Figure 2A). In the case that the MM value is close to the
PM value in every probe pair, it is presumably difficult to
separate a signal of specific binding from one of non-spe-
cific binding (Figure 2B). However, the value of X informs
as to whether a gene is truly expressed or not. Figure 2B-1
shows an 'On' gene (X = 8) and Figure 2B-2 shows an 'Off '
gene (X = 3). When gene expression intensity is low, it is
difficult to distinguish non-specific signal from total sig-
nal intensity (Figure 2C). Figure 2C-1 shows an 'On' gene
(X = 10) with low intensity. Figure 2C-2 shows an 'Off '
gene (X = 6) with low intensity. In this case, both PM and
MM values represent measures of non-specific binding.
Briefly, the value of X provides qualitative information as
to whether a gene is being expressed or not and it is more
informative, especially when the gene expression level is
not high. We propose to quantify a gene as being
expressed using a random variable Z derived from X and
assume that Z follows a Weibull-Normal mixture distri-
bution with two components corresponding to the sepa-
rate states 'On' and 'Off '. The probability of a gene being
'On' is obtained from the posterior probability using this
Weibull-Normal mixture distribution.
The results of applying the Weibull-Normal mixture
model to the Human Genome U95 data sets are shown in
Figure 3. The estimated parameter vector was
 = (1.00, 1.00, 0.35, 0.15), where μ and α
denote location and power parameters of the Weibull dis-
tribution, ξ denotes mixture rate of 'Off ' genes, and σ2
( , , , )m a x s 2
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Page 3 of 14denotes the variance of the Normal distribution. Figure
3A shows a comparison of the fitted Weibull-Normal dis-
tribution with two components ('On' and 'Off ') to the
empirical distribution. Figure 3B shows the correspond-
ing density function and its components. We defined the
gene state as 'On' if X ≥ 11 and 'Off ' if X ≤ 10. The vertical
dotted lines in Figures 3A and 3B correspond to X = 11.
Comparison between MAS5 calls and 'On/Off' calls 
usingspike-in genes
The MAS5 method also provides a qualitative evaluation
by calling gene expression present (P), marginal (M), or
absent (A) for each probe set in determining whether the
measured transcript is detected or not detected. How-
ever, there is an important difference between a gene
being 'Off ' and a call of 'absent'. In the cases of Figure 2B-
1 and 2C-1, for example, the probe sets were called
'absent' whereas their states were determined to be 'On'.
To make the detection call, the MAS5 method uses a
nonparametric statistical test (Wilcoxon signed rank test)
under the null hypothesis that PMs and MMs have the
same distribution [4]. The MAS5 method attempts to
identify truly expressed genes with certainty. Exclusion
probes that are called 'absent' can result in many false
negatives and loss of a large amount of information, espe-
cially with genes that switch between 'On' and 'Off ' with
different phenotypes. On the other hand, our method
seeks to correctly identify 'Off ' genes using an order rela-
tionship between PM and MM measures.
We compared 'On/Off ' calls with the MAS5 calls using
spike-in genes of the Human Genome U95 data sets. The
spike-in genes with 0 pM concentration were used as
negative controls (N = 59). The spike-in genes with more
than 0.25 pM concentration were used as positive con-
trols (N = 767). A cutoff point dividing gene states into
'On' and 'Off ' was determined as the minimum value of X
that contains as small an 'Off ' component as possible
using the fitted Weibull-Normal distribution (see 'Meth-
ods'). The value X = 11 was obtained as the cutoff point
and is shown by the vertical dotted lines in Figures 3A
and 3B. Table 1 shows the distribution of number of P/M/
A calls by MAS5 and number of On/Off genes for each
concentration of spike-in genes. As is shown in Table 2,
MAS5 calls generated many false negatives (19.0%) com-
pared to 'On/Off ' calls (8.7%). 'On/Off ' calls generated
Figure 1 Parallel boxplots of gene expression levels by RMA graded according to the value of X (number of pairs where PM>MM). A gene 
with high expression level has a large value of X, but large X does not necessary imply a high expression level; expression level of a gene with large X 
can vary from low to high.
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Figure 2 Comparison of PM and MM measurements within a probe set. Closed and open circles represent PM and MM measures, respectively. 
(A) High expression level. The PM value is suitably larger than MM value in every probe pair. Separating the signal of specific binding from that of non-
specific binding might be possible in such a case. (B) Moderate expression level. The MM value is near the PM value in every probe pair; separating 
the signal of specific bindings from that of non-specific binding is difficult. However, the value of X is informative as to whether a gene is truly being 
expressed or not. (B1) shows 'On' (X = 8)) and (B2) shows 'Off' (X = 3). (C) Low expression level. It is difficult to determine whether a gene is expressed 
or not. (C1) shows 'On' (X = 10) and (C2) shows 'Off' (X = 6).
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Figure 3 Results of applying the Weibull-normal mixture model to the Human Genome U95 data sets. (A) Comparison between the fitted 
Weibull-normal distribution (green line) with two components ('On' and 'Off') and the empirical distribution (brown line). The pink line shows the com-
ponent of expression intensities of 'On' genes and the blue line that of 'Off' genes. (B) Density function corresponding to the fitted Weibull-normal 
distribution function (green line) and its components (pink and blue lines).
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Page 6 of 146.8% false positives, although less than 4% (the boundary
p-value for defining Present calls) is desirable. The sensi-
tivities of the 'On/Off ' and MAS5 methods are shown in
Figure 4. The 'On/Off ' and MAS5 methods require at
least 0.5 pM and 2.0 pM of spike-in genes to achieve
around 80% sensitivity, respectively.
Identification of candidate genes for predicting 
neuroblastoma prognosis
Neuroblastoma is one of the most common solid tumors
in childhood. Its prognosis varies remarkably, ranging
from spontaneous regression to fatal progression [21].
We call these outcomes 'favorable' and 'unfavorable',
respectively. It is well known that MYCN amplification
strongly correlates with adverse outcome in neuroblas-
toma [22]. Nevertheless, whether MYCN expression is
truly predictive of neuroblastoma outcome remains con-
troversial [23]. We examined the relationship between
MYCN expression and clinical outcomes. A scatter dia-
gram of X (the number of probe pairs on an MYCN probe
set satisfying PM >MM) versus expression intensity of
MYCN is shown in Figure 5 for each neuroblastoma case.
Pink points represent cases with unfavorable outcome
and blue points represent those with favorable outcome.
A cross-tabulation of state of MYCN being 'On/Off ' and
outcome (favorable/unfavorable) is also shown in Figure
5, where we define the gene state as 'On' if X ≥ 7 and 'Off '
if X ≤ 6 according to the fit of the Weibull-Normal model.
The state of MYCN is uniformly 'Off ' in the favorable
group but variable--either 'On' or 'Off '--in the unfavor-
able group, suggesting that MYCN being 'On' is sufficient
for unfavorable outcome and that genes other than
MYCN are associated with poor prognosis. We then
introduce a new notation, 'OR_On' type gene, which
shows the logical relationship between multiple genes
and binary phenotypes.
Results of applying the Weibull-Normal mixture model
to 40 cases of neuroblastoma with favorable outcome and
21 cases with unfavorable outcome are shown in Figures
6A and 6B, respectively. The estimated parameter vectors
for favorable and unfavorable groups were  =
(1.96, 1.10, 0.17, 0.13) and (1.86, 1.16, 0.16, 0.14), respec-
tively, where μ and α denote location and power parame-
ters of the Weibull distribution, ξ denotes mixture rate of
'Off ' genes, and σ2 denotes the variance of the Normal
distribution. Figures 6A-1 and 6B-1 show the fitted
Weibull-Normal distribution with two components ('On'
( , , , )m a x s 2
Table 1: Comparison between Detection Call and On/Off method using spiked-in genes.
Detection Call On/Off
True concentration (pM) Present Marginal Absent X ≥ 11 X ≤ 10 Total
0 1 0 58 4 55 59
0.25 10 0 49 27 32 59
0.5 21 4 33 44 14 58
1.0 22 1 36 48 11 59
2 37 3 19 52 7 59
4 48 2 9 56 3 59
8 58 1 0 59 0 59
16 59 0 0 59 0 59
32 59 0 0 59 0 59
64 50 0 0 50 0 50
128 50 0 0 50 0 50
256 59 0 0 59 0 59
512 68 0 0 68 0 68
1024 69 0 0 69 0 69
Total 611 11 204 704 122 826
Table 2: False positive and negative rates by MAS5 and On/
Off methods.
False positive rate False negative rate
MAS5 1/59 (1.7%) 146/767 (19.0%)
ON/Off 4/59 (6.8%) 67/767 (8.7%)
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Page 7 of 14and 'Off ') and the empirical distribution. Figures 6A-2
and 6B-2 show the corresponding density functions and
their components. The cutoff point dividing genes into
'On' and 'Off ' states, X = 7, is denoted by the vertical dot-
ted lines in Figures 6A and 6B.
We set out to identify OR_On type genes involved in
neuroblastoma prognosis using the estimate of the proba-
bility of a gene being 'On' or 'Off ' (see 'Methods' section).
A hundred genes were selected as candidates from a total
of 54,109 genes. The five genes identified as candidate
genes involved in neuroblastoma progression were:
MYCN (neuroblastoma derived), NPW (neuropeptide
W), SLC30A3 (solute carrier family 30, member 3), MYC-
NOS (neuroblastome derived opposite strand), and
MYCN* (v-myc myelocytomatosis viral related onco-
gene). MYCN and MYCN* are the same genes detected by
different probes. MYCNOS and SLC30A3 were con-
firmed to be correlated with the status of expression of
MYCN in neuroblastoma [24,25]. For each of the selected
genes, the probability of being 'On' in the favorable group,
that in the unfavorable group, and the difference in prob-
ability of being 'On' between the unfavorable and favor-
able groups and its ranking, are listed in Table 3.
To assess the advantage of the 'On/Off ' method, we cal-
culated 'relative difference' statistics for the difference of
average of gene expression intensities between favorable
and unfavorable groups (the 'relative difference' statistic
was proposed by Tusher et al [26] to stabilize the t-value).
For each of the selected genes, average expression intensi-
ties obtained by the RMA methods and their standard
errors in the favorable and unfavorable groups, as well as
the ranking of 'relative difference' statistics in descending
order, are listed in Table 4. Accordingly, the OR_On type
genes are difficult to select based on the ranking of gene
expression intensities. The method based on the 'On/Off '
state of a gene performs better than the method based on
gene expression intensity.
Real-time RT-PCR was employed to verify whether the
four distinct selected genes were OR_On type genes.
Gene-expression features obtained by microarray data
analysis and Ct values from real-time RT-PCR for each of
these genes are shown in Figures 7A-D. The displayed
features are scatter diagrams of X and expression inten-
sity (RMA summarized value), parallel box plots of Ct
Figure 4 Sensitivities of On/Off calls and MAS5 calls using the spike in genes. The X-axis indicates log-transformed concentrations of spike-in 
genes; the Y-axis indicates true positive rates. Circles represent sensitivities by On/Off calls; triangles represent those by MAS5 calls.
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Page 8 of 14values in real-time RT-PCR for three groups -- favorable,
unfavorable 'On', and unfavorable 'Off ' (the latter two
groups abbreviated as 'unfavorable_On' and
'unfavorable_Off ') -- and parallel box plots of Ct values
from real-time RT-PCR of GAPDH according to the same
three groups. As mentioned above, the state of a gene was
defined as 'On' if X ≥ 7 and 'Off ' if X ≤ 6. Average Ct value
was significantly lower in the unfavorable_On group
compared with that in the favorable and unfavorable_Off
groups. This confirms that the selected genes were not
expressed in the favorable and unfavorable_Off groups
but were in the unfavorable_On group.
Discussion
MAS5 P/M/A calls are based on a nonparametric statisti-
cal test, in which the default state of a gene is 'absent'.
Therefore, it inevitably yields many false negatives which,
we think, is its main disadvantage. For example, BIRC5
(baculoviral IAP repeat-containing 5), also called sur-
vivin, which is a human gene that is a member of the
inhibitor of apoptosis (IAP) family, is expressed at high
levels in most human tumors but is completely absent in
terminally differentiated cells [27]. Figure 8 shows a dia-
gram of X and expression RMA intensities of BIRC5 for
each neuroblastoma case. BIRK5 was judged as 'On' in all
Figure 5 Scatter diagram of X and expression intensities of MYCN for each neuroblastoma case. The pink points represent cases with unfavor-
able outcome and the blue points those with favorable outcome. The relationship between MYCN state ('On/Off') and outcome (favorable/unfavor-
able) is listed, where the gene state 'On' is defined as X ≥ 7 and 'Off' is defined as X ≤ 6.
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Page 9 of 14of the 61 cases by our method but 12 cases, which are cir-
cled in Figure 8, were classified as 'absent' by MAS5. As is
shown in Table 2 or Figure 8, 'On/Off ' calls generated few
false negatives compared to MAS5 calls. Although the
poor separation of 'On' and 'Off ' components of the
Weibull-Normal mixture would result in false positives or
negatives, we think that it is due to a limitation of
microarray performance.
In this study, we only identified genes that switched
'On' and 'Off ' between phenotypes using an indicator
based on the probability of being 'On'. Of course, some
genes exhibit differences between phenotypes in terms of
their quantitative expression intensities, going from nor-
mal to abnormally increased or decreased. For example,
BIRC5 was judged as 'On' in all cases and, in addition,
'On' with 'abnormally increased intensity' predicted poor
diagnosis (unfavorable) except for one case that had been
detected by mass-screening at stage I followed by radical
resection. We further explored the genes whose intensity
levels changed quantitatively from normal to abnormal
between two different phenotypes, such as BIRC5, by cal-
culating the likelihoods under the null hypothesis that
gene expression intensities obey a normal distribution. As
a result, more than a thousand genes were selected as
candidates.
A method to create a gene expression barcode - genes
expected to be expressed are coded with ones and those
expected to be unexpressed are coded with zeros - was
developed by Zilliox and Irizarry [28]. Furthermore, an
algorithm for estimating expression states was described
Figure 6 Results of applying the Weibull-normal mixture model to the neuroblastoma data sets - A and B show the favorable and unfavor-
able group, respectively. (A1, B1). Comparison between the fitted Weibull-normal distribution (green line) with two components ('On' and 'Off') 
and the empirical distribution (brown line). The pink line shows the component of expression intensities of 'On' genes, the blue line that of 'Off' genes. 
(A2, B2) Density function corresponding to the fitted Weibull-normal distribution function (green line) and its components (pink and blue lines).
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Page 10 of 14by McCall et al. [29]. They state that the magnitude of the
unexpressed observed intensities differs among genes;
accordingly the distribution of observed intensities must
be estimated for each gene. Their method therefore
requires a large database of observed intensities across
many different tissues. We consider it natural that the
magnitude of the unexpressed observed intensities differs
by gene because unexpressed observed intensities include
gene dependent cross-hybridization. On the other hand,
our method can correct gene dependent cross-hybridiza-
tions by using MM probes. Therefore, it is unnecessary to
be concerned with differences in distribution of unex-
pressed observed intensities among genes. Several tens of
samples are enough to estimate it. Another characteristic
of our method is robustness, because it is based on the
order relationship between PM and MM values. Our
assumptions are just (1) the expected PM value is larger
than that of the MM value when a gene is expressed, and
(2) the expected PM value equals that of the MM value
when a gene is unexpressed. Although availability of MM
probes may be in doubt [10], our approach provides good
justification for the use of MMs.
Conclusion
The qualitative evaluation 'probability of a gene being
expressed' provides a useful indicator for improving the
performance of microarray data analysis. When expres-
sion intensity of a gene is not high, it is difficult to deter-
mine its real intensity after removing non-specific
binding. Especially in this case, 'probability of a gene
being expressed' gives useful qualitative information
complementing its true intensity. In regards to a practical
problem in expression array analysis, genes that switch
between 'On' and 'Off ' with different phenotypes can be
found with greater confidence. Our proposed method of
estimating 'probability of a gene being expressed' is
robust because it is not based on expression intensities
but rather is based on the order relationship between PM
and MM values.
Methods
Human Genome U95 data sets
The human genome U95 data sets consist of a series of 14
genes spiked-in at known concentrations (0, 0.25, 0.5, 1,
2, 4, 8, 16, 32, 64, 128, 256, 512, and 1024 pM) and
arranged in a Latin square format. Each subsequent
experiment rotates the spike-in concentrations by one
experimental group. The data consist of 14 spiked-in
genes in 14 experimental groups. Replicates within each
experimental group result in a total 59 CEL files.
Neuroblastoma samples
Total RNA was extracted from 61 neuroblastoma sam-
ples. Ages at diagnosis and stages at surgery according to
the INSS (International Neuroblastoma Staging System)
are shown in Additional file 1. All patients were diag-
Table 3: Top five genes selected using the probability of a gene being 'On'.
Based on the probability being 'On'
Gene FavorablePr_On UnfavorablePr_On Pr_On (Unfav.) -
Pr_On (Fav.)
Ranking
SlC30A3 0.26 0.89 0.63 1
MYCN* 0.38 0.94 0.56 2
MYCNOS 0.38 0.88 0.50 3
NPW 0.16 0.58 0.42 4
MYCN 0.19 0.58 0.39 5
Table 4: Ranking using 'relative difference' statistics.
RMA method
Gene Favorable
average (s.d.)
Unfavorable
average (s.d.)
Ranking
SlC30A3 4.93 (0.190) 5.40 (0.521) 100
MYCN** 4.59 (0.186) 5.21 (0.617) 17
MYCNOS 4.59 (0.152) 5.12 (0.523) 24
NPW 4.17 (0.106) 4.63 (0.670) 1016
MYCN 4.57 (0.161) 5.02 (0.508) 151
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Page 11 of 14nosed as having neuroblastoma between 1991 and 2005
at Hiroshima University Hospital or affiliated hospitals.
Most of the patients were treated according to the Japa-
nese neuroblastoma protocols for infants or advanced
stage NB (A1, new A1, or A3) [30]. The follow-up period
was more than 5 years for all patients. This research was
approved by the Ethics Committee of Hiroshima Univer-
sity (Hiro-Rin-20). Written informed consent was
obtained from parents of all patients. None of the
patients had therapy prior to surgery or biopsy.
Affymetrix microarray analysis
Microarray experiments were conducted according to
standard protocols for Affymetrix Genome U133 Plus 2.0
arrays (Affymetrix, Inc., Santa Clara, CA) [31]. Briefly,
using 1 μg of total RNA, cDNA and biotinated cRNA syn-
thesis was performed using the GeneChip expression 3'
amplification reagents (one-cycle cDNA synthesis, and
IVT labeling) kits of Affymetrix following the manufac-
turer's protocols. Fragmented cRNA was applied to the
hybridization and scanning of the array was performed
following the manufacturer's protocols. Experimental
details and all results are available at the Gene Expression
Omnibus, http://www.ncbi.nlm.nih.gov/geo/ (GEO
accession number GSE16237).
Quantitative RT-PCR
In each tumor sample, cDNA was synthesized from 5 μg
total RNA using a High Capacity cDNA Archive™ kit
(Applied Biosystems), and then a five-hundredth aliquot
of the cDNA (equivalent to 10 ng total RNA) was sub-
jected to real-time RT-PCR using Universal Probe
Library (UPL, Roche Diagnostics, Tokyo, Japan) for each
target gene, or an internal control GAPDH (glyceralde-
hyde-3-phosphatedehydrogenase) TaqMan™ probe
(Applied Biosystems) on an ABI PRISM™ 7900HT
sequence detection system (Applied Biosystems) with
384-well plates. The relative gene expression levels were
calculated as a ratio relative to GAPDH expression level.
Quantification of the likelihood that a gene is 'On'
Define a random variable , the specific value of
which indicates the order relationship between PM and
MM: i.e.,
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Figure 7 Gene-expression features assessed by microarray and Ct values in real-time RT-PCR for four unique selected genes. The genes se-
lected were: A: MYCN, B: MYCNOS, C: NPW, and D: SLC30A3. The first row shows scatter diagrams of X versus expression intensities for each case. Pink 
points represent cases with unfavorable outcome and blue points cases with favorable outcome. The second row shows parallel boxplots of Ct values 
in real-time RT-PCR by three groups: favorable, unfavorable_On, and unfavorable_Off. The third row shows parallel boxplots of Ct values in real-time 
RT-PCR of GAPDH for the same three groups.
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Page 12 of 14A set of probe level data for genes in an array i may be
described as
We introduce a random variable Z(g) defined as
to quantify the likelihood of a gene being expressed,
where  is added to avoid discontinuity at
 or 0 and N + 1 enhances the model fit.
When a gene g is sampled randomly, the random variable
Z = Z(g) is assumed to follow a mixture distribution with
two components corresponding to the separate states
'On' and 'Off '. We assume that Z may be expressed as the
sum of random variables T and X, where T expresses the
likelihood of a gene being expressed when in the 'On'
state and X expresses a random error having a normal
density function ϕ with mean zero and variance σ2. We
further assume that the density function of T is given by
f(t|μ, α, ξ) = ξδ (t) + (1-ξ) fw (t|μ, α) where fw denotes the
Weibull density function with location parameter μ and
power parameter α, δ denotes the Dirac function, and ξ
denotes the mixture rate of 'Off ' genes. Then the density
function of Z can be expressed as
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Figure 8 Scatter diagram of X versus expression intensities of BIRC5 for each neuroblastoma case. The pink points show cases with unfavorable 
outcome and the blue points show cases with favorable outcome. The cases called 'absent' by MAS5 are circled.
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Page 13 of 14Given a set of samples {z(g)| g = 1, , G}, the maximum
likelihood estimate  of θ is obtained by
maximizing . The posterior
probabilities with respect to the status of gene expression
can be written as
A cutoff value zc dividing gene states 'On' and 'Off ' is
determined as the lowest value of z satisfying Pr(y ≥ z | y
~ ϕ (0, σ 2)) smaller than α (0 ≤ α ≤ 1).
'AND' and 'OR' type genes
We presume the existence of 'AND' and 'OR' type genes
that show a logical relationship between gene status 'On/
Off ' and binary phenotype. They are defined as follows:
Definition 1: A gene g is defined as 'OR_On' in the case
that g+ leads to R+ (the gene being on is sufficient for unfa-
vorable outcome), 'OR_Off ' in the case that g- leads to R+
(the gene being off is sufficient for unfavorable outcome),
'AND_On' in the case that R+ implies g+ (the gene being on
is necessary for unfavorable outcome), and 'AND_Off ' in
the case that R+ implies g- (the gene being off is necessary
for unfavorable outcome), where the symbols R+ and R-
indicate the two outcome phenotypes and g+ and g- indi-
cate a gene being 'On' and 'Off ', respectively.
The frequency distribution of cases according to these
four types of genotype/phenotype relationship can be
expressed by a set of two-by-two tables (Table 5).
Identification of 'OR_On type genes involved in 
neuroblastoma
We set out to identify OR_On type genes involved in neu-
roblastoma prognosis using the estimate of the probabil-
ity of a gene being 'On' or 'Off '. OR_On type genes were
identified by the following procedure.
Step 1
Calculate the probability of a gene being 'On' in the favor-
able and unfavorable groups using formula (1).
Step 2
A gene set G1 satisfying two conditions--(1) uniformly
'Off ' in the favorable group and (2) varying 'On' and 'Off '
in the unfavorable group--is defined as
Step 3
Arrange the values of Pr(g is 'Off ' in the favorable group |
g  G1) in descending order and select the top 100 genes.
Then rearrange according to
in descending order.
Software
MAS5 and RMA expression indices were calculated using
the package affy [32,33] provided by BioConductor [34].
Fortran was used to perform all of the analyses.
Additional material
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Additional file 1 Neuroblastoma cases. The file contains the table 
including ages at diagnosis and stages at surgery according to the INSS 
(International Neuroblastoma Staging System) of 61 neuroblastoma cases.
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Table 5: Association between gene status and response with 'OR' and 'AND' type genes.
OR_On OR_Off AND_On AND_Off
R+ R- R+ R- R+ R- R+ R-
g+ a 0 N1- b N2 N1 c 0 d
g- N1- a N2 b 0 0 N2- c N1 N2- d
Total N1 N2 N1 N2 N1 N2 N1 N2
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MAS5: Affymetrix Microarray Suite version 5; MM: mismatch probe; PM: perfect
match probe; RMA: robust multi-array analysis.
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